Linesight supported the delivery of a new CAR T Cell Therapy facility designed to bring personalised treatments for blood cancers closer to patients across Europe and to reduce turnaround times for therapy production. The facility incorporated 4,720m² of GMP cleanrooms and 1,470m² of laboratory space, creating a substantial footprint to support advanced cell therapy manufacturing.
Delivered over a three-year period and completed in early 2025, the programme also included a temporary training facility, along with a temporary data centre connecting essential software, to accelerate operational readiness and reduce commissioning risk and support a smoother transition to full operation.
Linesight provided full commercial and project controls (Cost & Schedule) oversight across the project lifecycle, along with Equipment and Sub-Contract Procurement Support. These services established a clear commercial framework and ensured alignment across all delivery workstreams.
During delivery, the project faced increased complexity through changes in the project delivery structure, introducing risks to cost, schedule, and continuity. The transition required careful renegotiation of subcontracts to maintain commercial obligations and minimise disruption, while new governance, reporting and project controls procedures had to be rapidly established to restore programme stability. Strong change management and a tightly controlled schedule were essential to uphold the original programme intent and protect commercial certainty throughout this period.